Phio Names New CFO, SVP Regulatory to Drive PH-762 Clinical Milestones
Phio promoted Lisa Carson to CFO and Jennifer Phillips to SVP, Regulatory and Corporate Affairs, adding Kimberly Man as VP of Program Development to strengthen financial, regulatory and program leadership. These changes position Phio for upcoming regulatory engagements and drive PH-762 clinical milestones while sustaining PH-894 development.
1. Executive Team Realignment
Phio appointed Lisa Carson as CFO, Jennifer Phillips as Senior Vice President of Regulatory and Corporate Affairs, and Kimberly Man as Vice President of Program Development to bolster leadership. CEO Robert Bitterman emphasized these changes will support regulatory discussions and accelerate clinical progress for PH-762 while maintaining momentum on PH-894.
2. Financial Leadership Enhancement
Lisa Carson brings over 20 years of finance and accounting leadership from roles at Prelude Therapeutics, TELA Bio and PhaseBio Pharmaceuticals. In her new role, she will oversee financial operations, capital planning and reporting to ensure robust support for Phio’s clinical-stage programs.
3. Regulatory Strategy Focused on PH-762
Jennifer Phillips, Pharm.D., has more than 25 years of regulatory affairs experience at major pharmaceutical organizations including Aventis and Wyeth. She will lead regulatory strategy and agency engagement as PH-762 advances toward its next stage and key clinical milestones.
4. Program Development for Ongoing Trials
Kimberly Man, with over 20 years in program leadership and clinical operations at Sandoz and Cutanea Life Sciences, will manage day-to-day coordination of PH-762 and contribute to long-term strategic planning for PH-894’s development.